ARTICLE | Company News
Amgen, Zhejiang Beta Pharma Co. Ltd. sales and marketing update
May 20, 2013 7:00 AM UTC
Amgen and Zhejiang Beta formed a JV - Amgen-Beta Pharmaceuticals Co. Ltd. - to commercialize Amgen's colorectal cancer drug Vectibix panitumumab in China. Zhejiang Beta will hold a 51% stake in the JV, and Amgen will hold a 49% stake. Vectibix is in Phase III testing in China to treat colorectal cancer. The companies declined to disclose details. ...